Cancers · 2024 · 34 citations · 53 references
MedicineEndocrinologyOncologyDiabetologyDiabetes MellitusDiabetes PharmacotherapyGlucagon-like Peptide-1 Receptor AgonistsPancreatic CancerPancreatic DiseasesPancreatic EndocrinologyGlp-1 Receptor PharmacologyGlucagon Receptor AgonistsGlucagon-like Peptide 1 Receptor AgonismGlucagon-like Peptide 1 SignalingGlucagon-like Peptide-1 Receptor SignalingGlucagon-like PeptidesPancreatic Peptide HormonesType 2 Diabetes Treatment
BACKGROUND: GLP-1 RAs are widely used for T2DM treatment due to their cardiorenal and metabolic benefits. This study examines the risk of pancreatic cancer with GLP-1 RA use in patients with T2DM. METHODS: We analyzed TriNetX's deidentified research database using the U.S. Collaborative Network comprising 62 healthcare organizations across the U.S.A. Patients with T2DM were split into two cohorts: one receiving GLP-1 RAs, and one not receiving GLP-1 RAs. We excluded patients with known risk factors for pancreatic cancer, including pancreatic cysts, a personal or family history of BRCA1, BRCA2, CDKN2A, KRAS, MEN1, MLH1, MSH2, NOTCH1, PALB2, PMS2, and PRSS1S genes, family history of pancreatic cancer, and VHL syndrome. Using a 1:1 propensity score-matching model based on baseline characteristics and comorbidities, we created comparable cohorts. We then compared the rate of pancreatic cancer between the two cohorts at a 7-year interval. RESULTS: Out of 7,146,015 identified patients with T2DM, 10.3% were on a GLP-1 RA and 89.7% were not. Post-PSM, 721,110 patients were in each group. Patients on GLP-1 RAs had a 0.1% risk compared to a 0.2% risk of pancreatic cancer in the 7-year timeframe. CONCLUSION: The use of GLP-1 RAs in patients with type 2 diabetes mellitus (T2DM) does not appear to substantially elevate the risk of pancreatic cancer; in fact, it may potentially exert a protective effect.
53
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.4K citations · Full text
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter J. Bailey, David K. Chang, Kátia Nones et al. · Nature · 2016 · 3.7K citations
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sánchez-Vega, Marco Mina, Joshua Armenia et al. · Cell · 2018 · 3.4K citations · Full text
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Sunil R. Hingorani, Emanuel F. Petricoin, Anirban Maitra et al. · Cancer Cell · 2003 · 2.5K citations · Full text